Vitality Biopharma (OTCQB: VBIO) is focused on leveraging the power of cannabinoids to treat serious neurological and inflammatory disorders. The company has developed a new class of cannabinoid prodrugs (cannabosides), which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation. For more information, visit the company’s website at www.vitality.bio.
CBDWire (CBDW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, CBDW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information, visit https://www.cbdwire.com
Please see full disclaimers on the CBDWire website: http://nnw.fm/Disclaimer